I remind you that Acadia, in addition to the earnings at the end of February, is awaiting the data from the phase 3 study on negative symptoms in schizophrenia (fundamental for the future of Nuplazid) expected by March 31st, news can come out every day:
The Company expects to report top-line results from ADVANCE-2, a Phase 3 study evaluating pimavanserin for the treatment of the negative symptoms of schizophrenia in the first quarter of 2024
I remind you that Acadia, in addition to the earnings at the end...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |